scholarly journals Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

2019 ◽  
Vol 13 (1) ◽  
pp. e0007126 ◽  
Author(s):  
María Pilar Arenaz-Callao ◽  
Rubén González del Río ◽  
Ainhoa Lucía Quintana ◽  
Charles J. Thompson ◽  
Alfonso Mendoza-Losana ◽  
...  
Keyword(s):  
Buruli Ulcer ◽  
Beta Lactam ◽  
Ulcer Treatment

scholarly journals Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening

2018 ◽  
Author(s):  
María Pilar Arenaz Callao ◽  
Rubén González del Río ◽  
Ainhoa Lucía Quintana ◽  
Charles J. Thompson ◽  
Alfonso Mendoza-Losana ◽  
...  
Keyword(s):  
Inhibitory Concentration ◽  
Buruli Ulcer ◽  
Mycobacterium Ulcerans ◽  
Beta Lactam ◽  
Beta Lactams ◽  
Amoxicillin Clavulanate ◽  
Low Toxicity ◽  
Potential Use ◽  
Ulcer Treatment

ABSTRACTThe potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was investigated with representative classes analyzed in vitro for activity against Mycobacterium ulcerans. Beta-lactams tested were effective alone and displayed a strong synergistic profile in combination with antibiotics currently used to treat BU, i.e. rifampicin and clarithromycin; this activity was further potentiated in the presence of the beta-lactamase inhibitor clavulanate. In addition, quadruple combinations of rifampicin, clarithromycin, clavulanate and beta-lactams resulted in multiplicative reductions in their minimal inhibitory concentration (MIC) values. The MIC of amoxicillin against a panel of clinical isolates decreased more than 200-fold within this quadruple combination. Amoxicillin/clavulanate formulations are readily available with clinical pedigree, low toxicity, and orally and pediatric available; thus, supporting its potential inclusion as a new anti-BU drug in current combination therapies.

scholarly journals Barriers to Buruli ulcer treatment completion in the Ashanti and Central Regions, Ghana

2020 ◽  
Vol 14 (5) ◽  
pp. e0008369
Author(s):  
Shelui Collinson ◽  
Venus N. B. Frimpong ◽  
Bernadette Agbavor ◽  
Bethany Montgomery ◽  
Michael Oppong ◽  
...  
Keyword(s):  
Buruli Ulcer ◽  
Treatment Completion ◽  
Central Regions ◽  
Ulcer Treatment

scholarly journals Genomic analysis of ST88 community-acquired methicillin resistantStaphylococcus aureusin Ghana

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3047 ◽  
Author(s):  
Grace Kpeli ◽  
Andrew H. Buultjens ◽  
Stefano Giulieri ◽  
Evelyn Owusu-Mireku ◽  
Samuel Y. Aboagye ◽  
...  
Keyword(s):  
Core Genome ◽  
Buruli Ulcer ◽  
Genomic Analysis ◽  
Resource Limited ◽  
Public Health Information ◽  
Genomic Studies ◽  
Mrsa Strains ◽  
Genomic Regions ◽  
Pacbio Smrt Sequencing ◽  
Ulcer Treatment

BackgroundThe emergence and evolution of community-acquired methicillin resistantStaphylococcus aureus(CA-MRSA) strains in Africa is poorly understood. However, one particular MRSA lineage called ST88, appears to be rapidly establishing itself as an “African” CA-MRSA clone. In this study, we employed whole genome sequencing to provide more information on the genetic background of ST88 CA-MRSA isolates from Ghana and to describe in detail ST88 CA-MRSA isolates in comparison with other MRSA lineages worldwide.MethodsWe first established a complete ST88 reference genome (AUS0325) using PacBio SMRT sequencing. We then used comparative genomics to assess relatedness among 17 ST88 CA-MRSA isolates recovered from patients attending Buruli ulcer treatment centres in Ghana, three non-African ST88s and 15 other MRSA lineages.ResultsWe show that Ghanaian ST88 forms a discrete MRSA lineage (harbouring SCCmec-IV [2B]). Gene content analysis identified five distinct genomic regions enriched among ST88 isolates compared with the otherS. aureuslineages. The Ghanaian ST88 isolates had only 658 core genome SNPs and there was no correlation between phylogeny and geography, suggesting the recent spread of this clone. The lineage was also resistant to multiple classes of antibiotics includingβ-lactams, tetracycline and chloramphenicol.DiscussionThis study reveals thatS. aureusST88-IV is a recently emerging and rapidly spreading CA-MRSA clone in Ghana. The study highlights the capacity of small snapshot genomic studies to provide actionable public health information in resource limited settings. To our knowledge this is the first genomic assessment of the ST88 CA-MRSA clone.

scholarly journals Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment

2015 ◽  
Vol 9 (8) ◽  
pp. e0003996 ◽  
Author(s):  
Nicole Scherr ◽  
Gerd Pluschke ◽  
Charles J. Thompson ◽  
Santiago Ramón-García
Keyword(s):  
Buruli Ulcer ◽  
Ulcer Treatment

scholarly journals Steps Toward Creating A Therapeutic Community for Inpatients Suffering from Chronic Ulcers: Lessons from Allada Buruli Ulcer Treatment Hospital in Benin

2016 ◽  
Vol 10 (7) ◽  
pp. e0004602 ◽  
Author(s):  
Arnaud Setondji Amoussouhoui ◽  
Roch Christian Johnson ◽  
Ghislain Emmanuel Sopoh ◽  
Ines Elvire Agbo ◽  
Paulin Aoulou ◽  
...  
Keyword(s):  
Therapeutic Community ◽  
Buruli Ulcer ◽  
Chronic Ulcers ◽  
Ulcer Treatment

scholarly journals Buruli Ulcer: Treatment Challenges at Three Centres in Ghana

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Pius Agbenorku ◽  
Isaac K. Donwi ◽  
Pawson Kuadzi ◽  
Paul Saunderson
Keyword(s):  
Buruli Ulcer ◽  
Ulcer Treatment

scholarly journals Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa

2019 ◽  
Vol 13 (10) ◽  
pp. e0007866 ◽  
Author(s):  
Anita C. Wadagni ◽  
Jonathan Steinhorst ◽  
Yves T. Barogui ◽  
P. M. Catraye ◽  
Ronald Gnimavo ◽  
...  
Keyword(s):  
West Africa ◽  
Surgical Intervention ◽  
Buruli Ulcer ◽  
Treatment Rate ◽  
Ulcer Treatment
Sign in / Sign up

Export Citation Format

Share Document